Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.67 |
| ▸ | RELA | Q04206 | 4/20 | 0.67 |
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204132 | 0.90 | NOTUM (0.69) | NPC1RAB9ASMN1; SMN2NOTUMMAPT | |
| SCHEMBL9799093 | 0.90 | NOTUM (0.69) | NPC1RAB9ASMN1; SMN2NOTUMMAPT | |
| SCHEMBL4867294 | 0.89 | NOTUM (0.62) | SMN1; SMN2NOTUMMAPTTSHRKMT2A | |
| SCHEMBL5190086 | 0.84 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL22747804 | 0.83 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL24898029 | 0.82 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL157596 | 0.82 | MAPT (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14817503 | 0.81 | TSHR (0.67) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29449723 | 0.80 | NOTUM (1.00) | NPC1RAB9ASMN1; SMN2NOTUMMAPT | |
| SCHEMBL396037 | 0.80 | NOTUM (1.00) | NPC1RAB9ASMN1; SMN2NOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4217348-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BeiGene, Ltd. (KY) | 2023-08-02 | — | — | EP | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023288242-A1 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-5041154-A | Benzoxazine compounds useful as herbicides | UBE INDUSTRIES, LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0196570-B1 | BENZOAXAZINE DERIVATIVES AND HERBICIDAL COMPOSITION | UBE INDUSTRIES, LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
| EP-0196570-A1 | Benzoaxazine derivatives and herbicidal composition | UBE INDUSTRIES, LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4428881-A | PRE- AND POSTEMERGENCE HERBICIDES | GULF OIL CORPORATION (US) | 1984-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | FLT1, KDR, TEK | NPC1 2507/4885RAB9A 2294/4885SMN1; SMN2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.